8q24 amplification in transitional cell carcinoma of bladder

Applied Immunohistochemistry and Molecular Morphology

Volumn 11, Issue 1, 2003, Pages 33-36

  Visapää, Harri ^a,c   Seligson, David ^a   Eeva, Mervi ^b   Gaber, Flora ^a   Rao, Jian Yu ^a   Belldegrun, Arie ^a   Palotie, Aarno ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

8q24; Ki67; P53; Tissue microarray analysis; Transitional cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER TISSUE; CHROMOSOME 8Q; CHROMOSOME ARM; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0037344917     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200303000-00006     Document Type: Article

References (22)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Brandau S, Bohle A, Bladder cancer I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-7.
3. Richter J, Jiang F, Gorog J-P, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997:57:2860-4.
4. Richter J, Beffa L, Wagner U, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998;153:1615-21.
5. Fadl-Elmula I, Kytola S, Pan Y, et al. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer 2001;92:824-31.
6. Takahashi E, Hori T, O'Connell P, et al. Mapping of the MYC gene to band 8q24.12→q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization. Cytogenet Cell Genet 1991;57:109-11.
7. UCSC Human Genome Project Working Draft [web site]. Human Genome Browser, Aug. 6, 2001 Freeze. Available at: http://www.genome.ucsc.edu. Accessed January 7, 2002.
8. Boyd MT, Zimonjic DB, Popescu NC, et al. Assignment of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridization. Cytogenet Cell Genet 2000;90:64-5.
9. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci 1998;95:1735-40.
10. Wolf HK, Stober C, Hohenfellner R, et al. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22:328-36.
11. Shirahama T, Arima J, Akiba S, et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92:188-93.
12. Lavezzi AM, Biondo B, Cazzullo A, et al. The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res 2001;21:1279-84.
13. Knowles MA. What we could do now: molecular pathology of bladder cancer. J Clin Pathol 2001:54:215-21.
14. Slaton JW, Benedict WF, Dinney CPN. P53 in bladder cancer: mechanism of action, prognostic value, and target of therapy. Urology 2001;57:852-9.
15. Pfister C, Lacombe L, Vezina M-C, et al. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol 1999:30:1350-5.
16. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
18. Andersen CL, Hostetter G, Grigoryan A, et al. Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 2001;45:83-6.
19. Rao JY, Seligson D, Visapää H, et al. Tissue microarray analysis (TMA) of cytoskeletal actin associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 2002; in press.
20. Sauter G, Carroll P, Moch H, et al. C-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 1995;146:1131-9.
21. Kallioniemi A, Kallioniemi O-P, Citro G, et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995;12:213-9.
22. Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277:5484-9.